Natera gets Japan PMDA authorization for Signatera in bladder cancer
Natera said Japan’s PMDA authorized its Signatera test as a companion diagnostic in muscle-invasive bladder cancer to guide adjuvant atezolizumab treatment.
Natera, Inc. (NTRA) said its Signatera test has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency as a companion diagnostic in muscle-invasive bladder cancer. The approval supports use of the Signatera test to guide adjuvant ate…